Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2021 Apr;10(8):2618-2626.
doi: 10.1002/cam4.3784. Epub 2021 Mar 16.

Evaluation of the modified immune prognostic index to prognosticate outcomes in metastatic uveal melanoma patients treated with immune checkpoint inhibitors

Michael S Sander  1 , Igor Stukalin  2 , Isabelle A Vallerand  1   3 , Siddhartha Goutam  4 , Benjamin W Ewanchuk  1 , Daniel E Meyers  2 , Aliyah Pabani  2 , Don G Morris  2 , Daniel Y C Heng  2 , Tina Cheng  2
Affiliations

Evaluation of the modified immune prognostic index to prognosticate outcomes in metastatic uveal melanoma patients treated with immune checkpoint inhibitors

Michael S Sander et al. Cancer Med. 2021 Apr.

Abstract

Background: Metastatic uveal melanoma (MUM) is associated with poor survival and inferior response to immune checkpoint inhibitor (ICI) therapy when compared with metastatic cutaneous melanoma. Currently, prognostic biomarkers are lacking to guide treatment decisions.

Patients and methods: We conducted a multicenter, retrospective cohort study using a centralized, province-wide cancer database in Alberta, Canada. We identified 37 patients with histologically confirmed MUM who received at least one dose of single-agent pembrolizumab or nivolumab, or combination therapy nivolumab and ipilimumab. A modified immune prognostic index (IPI), based on the previously reported lung immune prognostic index, was used to stratify patients into favorable and poor IPI groups. Survival analyses were conducted using the Kaplan-Meier method and Cox proportional hazards models, adjusting for baseline age (≥60) and ECOG performance status, to assess the associations between IPI and overall survival (OS). Time to treatment failure (TTF) was also assessed using the Kaplan-Meier method. The association between IPI and objective response rate was examined using chi-squared tests. Logistic regression was used to determine the association between IPI and immune-related adverse events (irAEs).

Results: Median OS was 15.6 (range 0.6-57.6) months with 45.9% 1-year survival rate at a median follow-up of 11.8 months. We found that a favorable IPI was significantly associated with OS [median 30.5 (12.0-not reached) months in the favorable IPI group compared with 4.6 (2.1-16.0) months in the poor IPI group (p = 0.001)] (HR=4.81, 95% CI; 1.64-14.10, p = 0.004), TTF [median 5.1 (95% CI; 2.1-10.4) months in the favorable IPI group compared with 3.7 (95% CI; 1.4-6.4) months in the poor IPI group (p = 0.0191)], and irAE (HR=6.67, 95% CI; 1.32-33.69, p = 0.0220).

Conclusions: The modified IPI may be a useful tool in clinical practice for identifying MUM patients who are more likely to experience irAEs and realize a survival benefit from ICI treatment.

Keywords: biomarkers; melanoma; prognosis; prognostic factor; survival.

PubMed Disclaimer

Conflict of interest statement

The authors have declared no conflict of interest.

Figures

FIGURE 1
FIGURE 1
Kaplan‐Meier curve depicting overall survival of patients with favorable and poor immune prognostic index (IPI) scores.
See this image and copyright information in PMC

References

    1. Johansson PA, Brooks K, Newell F, et al. Whole genome landscapes of uveal melanoma show an ultraviolet radiation signature in iris tumours. Nat Commun. 2020;11(1):1‐8. 10.1038/s41467-020-16276-8 - DOI - PMC - PubMed
    1. Krauthammer M, Kong Y, Ha BH, et al. Exome sequencing identifies recurrent somatic RAC1 mutations in melanoma. Nat Genet. 2012;44(9):1006‐1014. 10.1038/ng.2359 - DOI - PMC - PubMed
    1. Chattopadhyay C, Kim DW, Gombos DS, et al. Uveal melanoma: from diagnosis to treatment and the science in between. Cancer. 2016;122(15):2299‐2312. 10.1002/cncr.29727 - DOI - PMC - PubMed
    1. Kujala E, Mäkitie T, Kivelä T. Very long‐term prognosis of patients with malignant uveal melanoma. Invest Ophthalmol Vis Sci. 2003;44(11):4651‐4659. 10.1167/iovs.03-0538 - DOI - PubMed
    1. Jensen OA. Malignant melanomas of the human uvea: 25‐year follow‐up of cases in Denmark, 1943–1952. Acta Ophthalmol. 1982;60(2):161‐182. 10.1111/j.1755-3768.1982.tb08371.x - DOI - PubMed

Publication types

Substances